Immunotherapy after chemotherapy and bladder removal for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a new immunotherapy drug called sasanlimab as a maintenance treatment after chemotherapy and bladder removal surgery. The goal is to see if it helps keep the cancer from coming back in people with muscle-invasive bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have muscle-invasive bladder cancer (cancer has grown into the muscle layer) and are planning to have your bladder removed (cystectomy).
- You are able to receive chemotherapy with gemcitabine and cisplatin before surgery.
- You are in generally good health, able to do most daily activities on your own.
- You have not had chemotherapy or other anti-cancer treatment for this bladder cancer before.
- You do not have an active autoimmune disease (like lupus or rheumatoid arthritis) that would worsen with this immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study looks at how chemotherapy given before bladder removal surgery changes the immune environment around the tumor. The goal is to see if these changes can help predict how well the treatment works, which could lead to better personalized care.
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This study tests a combination of two chemotherapy drugs and an immunotherapy drug given before and after surgery to remove the bladder. It aims to see if this treatment is safe and well-tolerated in patients with muscle-invasive bladder cancer.
This trial tests a combination of two drugs—an antibody-drug conjugate (a targeted therapy that delivers cancer-killing medicine directly to cells) and an immunotherapy that helps your immune system fight cancer. The goal is to see if this combo works better than the standard chemoradiotherapy for bladder cancer when you keep your bladder.
Hear when a new MIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.